CNS Pharmaceuticals (CNSP) Amortizatization of Intangibles (2018 - 2019)
CNS Pharmaceuticals' (CNSP) quarterly Amortizatization of Intangibles came in at $9165.0 in Q2 2019, up 2.78% on a QoQ basis from $8917.0 in Q1 2019.
CNS Pharmaceuticals (CNSP) Amortizatization of Intangibles (2018 - 2019) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 2 years of Amortizatization of Intangibles data on file, last reported at $9165.0 in Q2 2019.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $9165.0 in Q2 2019, while the trailing twelve-month figure through Mar 2020 was $9165.0 (changed N/A YoY) and the FY2019 annual result came in at $18082.0, changed 0.0% from the prior year.
- Amortizatization of Intangibles grew to $9165.0 in Q2 2019, from $8917.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $12667.0 in Q3 2018 to a low of $3337.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 9,165.00 |
| Jun 30, 2019 | 9,165.00 |
| Mar 31, 2019 | 8,917.00 |
| Mar 31, 2019 | 8,917.00 |
| Dec 31, 2018 | 3,337.00 |
| Dec 31, 2018 | 3,337.00 |
| Sep 30, 2018 | 12,667.00 |
| Sep 30, 2018 | 12,667.00 |